# Gilead Sciences, Inc. (GILD)

> Source: Nexqual · https://nexqual.com/GILD · data as of 2026-10-22 20:00 UTC · cite as "Nexqual, Gilead Sciences, Inc. (GILD), nexqual.com/GILD" · informational, not investment advice.

**Price:** USD 157.19 (+2.36% on the day) · last close of Oct 22, 2026; US market pre market, not a live price. Prev close 153.57 · day 153–157.42 · 52w 114.02–160.51 · market cap $195B · NMS

## Key facts
- Last four reported quarters (through Jun 30, 2026): revenue $30.5B, net income -$3.24B (-10.6% margin), free cash flow $12.9B (SEC filings).
- 3 of 80 tracked superinvestors hold GILD (13F, Q2 2026): 0 new, 0 added, 2 reduced, 1 unchanged.
- Total return with dividends: 1Y +33.4% vs S&P 500 +14.9%; 5Y +179.3% vs S&P 500 +80.3%.
- Next earnings: 2026-10-29, EPS estimate USD 2.2, revenue estimate $7.81B.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $27.3B | $27.3B | $27.1B | $28.8B | $29.4B | $30.5B |
| Gross profit | $20.7B | $21.6B | $20.6B | $22.5B | $23.2B | — |
| Operating income | $9.92B | $7.33B | $7.61B | $1.66B | $10.0B | -$2.50B |
| Net income | $6.22B | $4.59B | $5.67B | $480M | $8.51B | -$3.24B |
| EPS (diluted) | $4.93 | $3.64 | $4.50 | $0.38 | $6.78 | — |
| Free cash flow | $10.8B | $8.34B | $7.42B | $10.3B | $9.46B | $12.9B |
| Gross margin | 75.8% | 79.3% | 76.0% | 78.3% | 78.8% | — |
| Operating margin | 36.3% | 26.9% | 28.0% | 5.8% | 34.0% | -8.2% |
| Net margin | 22.8% | 16.8% | 20.9% | 1.7% | 28.9% | -10.6% |
| Revenue growth | +10.6% | -0.1% | -0.6% | +6.0% | +2.4% | — |
| Cash + short-term investments | $6.52B | $6.38B | $7.26B | $9.99B | $7.63B | — |
| Total debt | $26.7B | $25.2B | $25.0B | $26.7B | $24.9B | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/S 6.4x · EV/Sales 7.2x · P/FCF 15.1x · P/B 16.5x · FCF yield 6.64% · Earnings yield -1.66% · Dividend yield (paid, TTM) 2.09% · Buyback yield (TTM) 0.74% · Net debt $23.1B · EV $218B
P/E at fiscal year-ends: Dec 2025 18.1x, Dec 2024 241.5x, Dec 2023 18.0x.

## Superinvestors (SEC 13F-HR, Q2 2026)
3 of 80 tracked investors hold GILD. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Dodge & Cox Funds | Dodge & Cox | 1.57% | $2.99B | Reduced -2.4% |
| John Rogers | Ariel Investments | 0.25% | $24.7M | Reduced -3.3% |
| Mairs & Power | Mairs & Power Funds | <0.01% | $287K | Unchanged |

## Analysts
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-20 | B of A Securities | Target raised | Buy | $168 → $172 |
| 2026-10-08 | RBC Capital | Target raised | Sector Perform | $123 → $126 |
| 2026-10-08 | Cantor Fitzgerald | Reiterated | Overweight | $155 |
| 2026-10-07 | Truist Securities | Target raised | Buy | $150 → $158 |
| 2026-10-07 | JP Morgan | Target raised | Overweight | $160 → $170 |
| 2026-10-07 | Morgan Stanley | Target lowered | Overweight | $165 → $163 |
| 2026-09-10 | HSBC | Target raised | Buy | $155 → $175 |
| 2026-08-05 | RBC Capital | Target raised | Sector Perform | $120 → $123 |
| 2026-08-05 | Cantor Fitzgerald | Reiterated | Overweight | $155 |
| 2026-08-05 | Needham | Reiterated | Buy | $170 |
| 2026-07-29 | Barclays | Target lowered | Equal-Weight | $155 → $145 |
| 2026-07-27 | Morgan Stanley | Target lowered | Overweight | $166 → $165 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-23) | 5Y (from 2021-10-18) |
|---|---|---|
| Total return | +33.4% | +179.3% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +33.5% | +22.8% |
| Volatility (annualized) | 26.7% | 23.8% |
| Max drawdown | -21.6% (Feb 2026→Jun 2026) | -25.6% (Jan 2024→May 2024) |

## Peers (Drug Manufacturers - General)
NVO (Novo Nordisk A/S) USD 39.43 +0.95% · PFE (Pfizer, Inc.) USD 30.42 +1.91% · AMGN (Amgen Inc.) USD 447.28 +2.04% · AZN (AstraZeneca PLC) USD 172.57 +2.45% · BMY (Bristol-Myers Squibb Company) USD 63 +3.08% · NVS (Novartis AG) USD 156.27 +1.52%

## More
Full page: https://nexqual.com/GILD · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Supply chain and relationships (SEC annual reports)


Other companies that name GILD in their own reports (relationship from GILD's side):

| Relationship | Company | Their filing | Sentence |
|---|---|---|---|
| partner | Kyverna Therapeutics, Inc. (KYTX) | 10-K 2026-03-26 | "In January 2020, the Company entered into the Collaboration, Option and License Agreement (the "Gilead Agreement") with Gilead Sciences, Inc. ("Gilead")." |
| supplier | VEEVA SYSTEMS INC (VEEV) | 10-K 2026-03-20 | "Our life sciences customers range from the largest global pharmaceutical and biotechnology companies such as Bayer AG, Boehringer Ingelheim GmbH, Eli Lilly and Company, Gilead Sciences, Inc., Merck Sh…" |
| partner | Cellectis S.A. (CLLS) | 20-F 2026-03-20 | "Autologous and Allogeneic CAR T-cell space: Bristol-Myers Squibb, Gilead Sciences Inc., Novartis AG, Johnson & Johnson, Regeneron Pharmaceuticals Inc., Fate Therapeutics Inc., CRISPR Therapeutics Inc.…" |
| partner | ASSEMBLY BIOSCIENCES, INC. (ASMB) | 10-K 2026-03-19 | "our ability to realize the potential benefits of our collaboration with Gilead Sciences, Inc. (Gilead), including all financial aspects of the collaboration and equity investments;" |
| partner | Gossamer Bio, Inc. (GOSS) | 10-K 2026-03-17 | "Pursuant to the terms of the license agreement with Pulmokine, Gilead Sciences and the Rensselaer Center for Translational Research, Inc., the licensors may have the right to control enforcement of ou…" |
| partner | AGENUS INC (AGEN) | 10-K 2026-03-16 | "For example, in February 2015, we began a broad collaboration with Incyte to pursue the discovery and development of antibodies, in December 2018 we entered into a partnership with Gilead relating to …" |
| partner | MACROGENICS INC (MGNX) | 10-K 2026-03-09 | "We are also collaborating with Gilead Sciences, Inc. (Gilead) on the development of MGD024, a bispecific DART molecule targeting CD123 and CD3 that utilizes our next-generation T-cell engager technolo…" |
| partner | Tango Therapeutics, Inc. (TNGX) | 10-K 2026-03-05 | "For some of our product candidates, we may decide to collaborate with other pharmaceutical and biotechnology companies, like our existing collaboration with Gilead, for the development and potential c…" |
| partner | Kymera Therapeutics, Inc. (KYMR) | 10-K 2026-02-26 | "In June 2025, we announced a strategic collaboration with Gilead Sciences, Inc. ("Gilead") to develop novel oral molecular glue degraders for CDK2." |
| partner | Arcus Biosciences, Inc. (RCUS) | 10-K 2026-02-25 | "•We expect to depend on our collaboration with Gilead for the research, development, manufacture and commercialization of certain of our investigational products." |
| partner | Xencor Inc (XNCR) | 10-K 2026-02-25 | "In January 2020, the Company entered into a Technology License Agreement (the "Gilead Agreement") with Gilead, pursuant to which the Company granted Gilead an exclusive license to its Cytotoxic Fc and…" |
| customer | IDEAYA Biosciences, Inc. (IDYA) | 10-K 2026-02-17 | "our ability to maintain existing, and establish new, strategic collaborations, licensing or other arrangements and the financial terms of any such agreements, including our Clinical Study Collaboratio…" |
| partner | Nurix Therapeutics, Inc. (NRIX) | 10-K 2026-01-28 | "Our partnered drug discovery pipeline consists of a clinical stage degrader of IRAK4 (NX-0479/GS-6791), a preclinical stage degrader of STAT6, currently in investigational new drug application (IND), …" |

## Revenue by product line (quarter ended 2026-06-30)

| Line | Revenue | Share | YoY |
|---|---|---|---|
| Product sales | $7.63B | 97.7% | +8.1% |
| Total HIV | $5.69B | 73.0% | +11.9% |
| Biktarvy | $3.77B | 48.3% | +6.9% |
| Descovy | $967.0M | 12.4% | +48.1% |
| Total Liver Disease | $877.0M | 11.2% | +10.3% |
| Total Oncology | $873.0M | 11.2% | +2.8% |
| Trodelvy | $457.0M | 5.9% | +25.5% |
| Total Cell Therapy | $417.0M | 5.3% | -14.0% |
| Yescarta | $346.0M | 4.4% | -12.0% |
| Sofosbuvir/Velpatasvir | $303.0M | 3.9% | -11.4% |
| Genvoya | $289.0M | 3.7% | -23.3% |
| Vemlidy | $289.0M | 3.7% | +14.7% |
| Odefsey | $239.0M | 3.1% | -19.8% |
| Yeztugo | $232.0M | 3.0% | +1446.7% |
| Royalty, contract and other revenues | $176.0M | 2.3% | +551.9% |
| Livdelzi | $167.0M | 2.1% | +114.1% |
| Total Other | $161.0M | 2.1% | -20.3% |
| Symtuza - Revenue share | $138.0M | 1.8% | +11.3% |
| Other Liver Disease | $118.0M | 1.5% | -4.1% |
| AmBisome | $110.0M | 1.4% | -14.7% |
| Tecartus | $70.0M | 0.9% | -23.9% |
| Other HIV | $56.0M | 0.7% | -39.1% |
| Other | $51.0M | 0.7% | -30.1% |
| Veklury | $23.0M | 0.3% | -81.0% |
| Total revenue | $7.80B | 100% | — |
The lines above cover 300.5% of total revenue.

## Revenue by region (quarter ended 2026-06-30)

| Line | Revenue | Share | YoY |
|---|---|---|---|
| U.S. | $5.60B | 71.8% | +10.9% |
| Europe | $1.32B | 17.0% | +11.4% |
| Rest of World | $876.0M | 11.2% | +4.0% |
| Total revenue | $7.80B | 100% | — |

## Company outlook (8-K filed 2026-08-04)

- "Additional information and a reconciliation between GAAP and non-GAAP financial information for the 2026 guidance is provided in the accompanying tables."

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $2.20 | $2.21 | -0.1% | $7.81B | 22 |
| Next quarter (ends 2026-12-31) | $2.16 | $2.26 | -4.3% | $8.20B | 20 |
| Current fiscal year (ends 2026-12-31) | $-0.40 | $-0.77 | -48.1% | $30.78B | 27 |
| Next fiscal year (ends 2027-12-31) | $9.98 | $9.63 | +3.6% | $32.90B | 26 |